Glytec Company Profile

Background

Overview

Glytec, founded in 2006, is a leading provider of AI-powered technology platforms specializing in diabetes and insulin management. The company is headquartered in Waltham, Massachusetts, with additional offices in Greenville, South Carolina. Glytec's mission is to enhance patient safety and outcomes by delivering personalized insulin dosing solutions across the continuum of care. Its flagship product, Glucommander®, is the first FDA-cleared cloud-based insulin management software, trusted by over 350 hospitals nationwide.

Mission and Vision

Glytec aims to revolutionize diabetes care by providing healthcare providers with advanced tools to manage insulin therapy effectively, thereby improving patient outcomes and reducing healthcare costs. The company's vision is to empower clinicians with data-driven insights and decision support technology to deliver highly individualized and proactive care for diabetes and related conditions.

Industry Significance

In 2021, Glytec was recognized on the Inc. 5000 list, ranking No. 3,953, highlighting its rapid growth and impact in the healthcare technology sector. The company's innovative solutions address critical challenges in diabetes management, contributing to improved patient safety and optimized clinical workflows.

Key Strategic Focus

Core Objectives

Glytec focuses on enhancing insulin management through AI-driven solutions, aiming to:

Improve patient safety and outcomes

Reduce hospital length of stay

Decrease readmission rates

Streamline clinical workflows

Areas of Specialization

The company specializes in:

Inpatient and outpatient insulin dosing

Glycemic management

Clinical decision support

Data analytics

Key Technologies Utilized

Glytec employs:

FDA-cleared Glucommander® software

AI and machine learning algorithms

Cloud-based infrastructure

Electronic health record (EHR) integration

Primary Markets Targeted

The company primarily serves:

Hospitals

Health systems

Clinics

Healthcare providers

Financials and Funding

Funding History

Glytec has secured significant funding to support its growth and innovation:

April 2021: Raised $21 million, comprising $9 million in debt financing from Silicon Valley Bank and $12 million in equity investments led by Savitr Capital.

June 2025: Secured an additional $36 million in growth investment led by Savitr Capital and Hayfin Capital Management to accelerate platform expansion and innovation.

Utilization of Capital

The funds are allocated towards:

Expanding research and development initiatives

Scaling the platform

Enhancing product offerings

Attracting top-tier talent

Pipeline Development

Key Pipeline Candidates

Glytec's primary focus is on:

Enhancing the Glucommander® software

Developing new technologies to address diabetes and related co-morbidities

Stages of Development

The company is in the advanced stages of:

Product development

Clinical validation

Target Conditions

Glytec targets:

Diabetes

Hyperglycemia

Hypoglycemia

Anticipated Milestones

The company anticipates:

Further product enhancements

Increased market adoption

Regulatory approvals

Technological Platform and Innovation

Proprietary Technologies

Glytec's proprietary technologies include:

Glucommander® software

AI-driven analytics

Clinical decision support systems

Significant Scientific Methods

The company utilizes:

Real-time and historical data analysis

Machine learning algorithms

Predictive analytics

Leadership Team

Key Executives

Patrick Cua: Chief Executive Officer (CEO)

Former executive at Humana and LetsGetChecked

Joined Glytec in 2024

Erik Eaker: Chief Operating Officer (COO)

Former executive at Humana and LetsGetChecked

Joined Glytec in 2024

Ashley Reynolds, PhD, MSN, RN: Chief Product and Experience Officer

Over 30 years of healthcare experience

Joined Glytec in 2024

Matt McPherson: Chief Financial Officer (CFO)

Over 20 years in healthcare and SaaS sectors

Joined Glytec in 2024

Leadership Changes

In January 2024, Glytec expanded its executive team with the appointments of Erik Eaker as COO, Ashley Reynolds as Chief Product and Experience Officer, and Matt McPherson as CFO to drive innovation and growth.